Current Report Filing (8-k)
23 September 2017 - 6:31AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): September 22, 2017 (September 18, 2017)
______________________________
Neuralstem, Inc.
(Exact name of registrant as specified
in Charter)
Delaware
|
|
001-33672
|
|
52-2007292
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2
nd
Floor, Germantown, Maryland 20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of
the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
|
Item 5.02.
|
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers
|
On September 18, 2017, the board of directors
(“Board”) of Neuralstem, Inc. (the “Company”) filled two vacancies in the Board with the appointments of
Cristina Csimma, Pharm.D, MHP and Zhuo Zhang. Pursuant to their respective appointments, the Board currently has 7 acting directors.
Mr. Zhang has been designated the director of the Series A 4.5% Convertible Preferred Stock (“Series A Stock”) per
his appointment by Tianjin Pharmaceuticals Group International Holdings Co., LTD (the sole holder of the Series A Stock). Dr. Csimma
and Mr. Zhang will both serve as Class III directors until the Company’s 2020 annual shareholders meeting or until such time
as they resign or are removed.
There are no family relationships among
Dr. Csimma or Mr. Zhang and any of our executive officers or directors.
As compensation for their services on the
Board, Dr. Csimma and Mr. Zhang will participate in the Company’s non-executive board compensation plan as described in the
Company’s Current Report on Form 8-K filed on June 27, 2017.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: September 22, 2017
|
Neuralstem, Inc.
|
|
|
|
|
|
|
|
|
/s/ Richard Daly
|
|
|
By: Richard Daly
|
|
|
Chief Executive Officer
|
|
|
|
|
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024